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Abstract
Background: Recent data have shown that HTLV-1 is prevalent among HIV positive patients in
Mozambique, although the impact of HTLV-1 infection on HIV disease progression remains
controversial. Our aim was to determine the phenotypic profile of T lymphocytes subsets among
Mozambican patients co-infected by HIV and HTLV-1.
Methods: We enrolled 29 patients co-infected by HTLV-1 and HIV (co-infected), 59 patients
mono-infected by HIV (HIV) and 16 healthy controls (HC), respectively.
For phenotypic analysis, cells were stained with the following fluorochrome-labeled anti-human
monoclonal antibodies CD4-APC, CD8-PerCP, CD25-PE, CD62L-FITC, CD45RA-FITC.
CD45RO-PE, CD38-PE; being analysed by four-colour flow cytometry.
Results: We initially found that CD4+ T cell counts were significantly higher in co-infected, as
compared to HIV groups. Moreover, CD4+ T Lymphocytes from co-infected patients presented
significantly higher levels of CD45RO and CD25, but lower levels of CD45RA and CD62L, strongly
indicating that CD4+ T cells are more activated under HTLV-1 plus HIV co-infection.
Conclusion: Our data indicate that HTLV-1/HIV co-infected patients progress with higher CD4+
T cell counts and higher levels of activation markers. In this context, it is conceivable that in co-
infected individuals, these higher levels of activation may account for a faster progression to AIDS.
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Background
Infection by the Human Immunodeficiency Virus (HIV)
has been considered a serious infectious disease particu-
larly in Southern Africa, which harbors more than 2/3 of
all worldwide cases of HIV [1].
The emergence of several co-pathogens has aggravated
this scenario in resource-limited settings [2,3]. Human T-
lymphotropic virus type 1 (HTLV-1) has been implicated
as a frequent co-pathogen in areas or groups where both
viruses are prevalent [4,5]. In the southern Africa region
where HIV is highly prevalent [6], the prevalence of co-
infection by HTLV-1 and HIV varies among countries and
in several places have been reported be higher than 10%
[7-9]. A recent study conducted in Mozambique reported
a co-infection prevalence rate of 4.5% among HAART
naïve HIV positive individuals. Thus, it is conceivable that
the impact of chronic infection by HTLV-1 on HIV disease
progression is a relevant issue in AIDS research. Neverthe-
less, such an issue remains controversial, and published
data are conflicting[10-12]. If in one hand it was initially
postulated that co-infected patients progress faster to
AIDS[13], further studies reported contradictory
results[10,14].
The influence of HTLV-1 on HIV disease progression has
been tightly linked, not only to several molecular events
[15,16] but to its potential to induce high levels immune
activation [17]. Although the mechanisms by which
chronic activation induced by HTLV-1 could potentially
affect the progression to AIDS are not completely under-
stood, we have learned from the natural history of HIV
infection that chronic activation of the immune system
takes part and triggers a number of cellular and molecular
pathways related to CD4+ T cell loss and immune deregu-
lation [18-22]. In this context, HTLV-1 per se induces a
strong immune activation [23,24] that has been associ-
ated to immunosuppression, unresponsiveness and
immune deregulation [25,26]. How the immune system
behaves in the presence of both HIV and HTLV-1 remains
to be clarified.
The concern regarding the clinical outcome as a result of
co-infection by HTLV-1 and HIV has gained a special rele-
vance in recent years, in face of the growing body of evi-
dence showing that: a) co-infection is prevalent in several
geographical regions in Southern Africa [27,28]; b) we
and others showed that co-infected patients present stable
CD4+ T lymphocytosis irrespective of their progression to
AIDS, which by certain extent could mask the immuno-
suppression with consequent inappropriate therapeutic
decisions in terms of the initiation of Highly Active Anti
Retroviral Therapy (HAART) and prophylaxis for oppor-
tunistic infections [29,30].
The situation has being aggravated by the fact that neither
cure nor effective treatment is yet available for HTLV infec-
tion [31] in such a way that clinicians are unable to con-
trol the effects exerted by the virus.
Previous studies have enrolled patients with different
HAART experiences and some authors believe that this
may partially explain the divergence of results obtained
[11]. Other studies were based on in vitro manipulation
[15] or used simian models [32]. In addition, no study has
been so far conducted in Africa, the region carrying the
greatest burden of HIV disease and where the epidemiol-
ogy of HIV and other diseases is quite different [1].
Altogether, these data raise the need to define to what
extent HTLV-1 impacts the clinical progression to AIDS in
an African setting. We evaluated herein HTLV-1 and HIV
co-infected HAART naïve adult patients, in terms of T cell
phenotype, further correlating the expression of activation
markers and HIV-1 viral load. We showed that co-infected
patients progress with higher levels of CD4+  T cells
expressing activation markers and a massive loss of naïve
cells, thus suggesting that co-infected patients progress
faster to AIDS.
Methods
Study design and subjects
A case control study was conducted with participants con-
sisting of three sets, namely, individuals co-infected by
HIV and HTLV-1 (Co-infected), HIV mono-infected
patients (HIV) and healthy controls (HC). Co-infected
and HIV groups were recruited from an ongoing cohort of
HIV infected patients followed in the Alto Maé Health
Centre, in the city of Maputo, Mozambique. In the period
between March and June 2006, 724 HIV 1/2 infected
patients were invited to participate and 704 (97.4%)
accepted to be part of this study. They were all screened for
HTLV-1 infection and 32 patients (4.5%, 32/704) were
founded to be co-infected by HTLV-1 and HIV. Three
patients with a positive HTLV-1 antibody test did not
return to collect their result and were excluded of the
study. Co-infected were matched at a ratio 1:2 with HIV
mono-infected by age, sex and HIV clinical stage system as
defined by WHO [33]. Co-infected and HIV mono-
infected were matched without prior knowledge of
CD4+T cell counts results.
Healthy controls were not matched by age and sex as we
did with co-infected and HIV-mono-infected, since they
were recruited on a consecutive basis from the routine
blood donors at the blood bank of Maputo Central Hos-
pital. In addition, most of blood donors are males and
younger as demonstrated by two previous studies con-
ducted at the same Blood Bank ([34,35]) Informed con-
sent to participate in the study was requested to allBMC Infectious Diseases 2009, 9:211 http://www.biomedcentral.com/1471-2334/9/211
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participants, and the study was approved by the National
Bioethics Committee in Mozambique and by the Sydney
University Ethics Committee, Australia.
Physical and neurological examination was performed by
two medical doctors blinded for the HTLV-1 status. Socio-
demographic data, sexual/reproductive history and clini-
cal data were also recorded from each participant.
The study population consisted of 59 HIV, 29 co-infected
and 16 healthy controls individuals. All HIV and co-
infected individuals were naïve to HAART. The median
age was 40 years (IQR, 34 - 48 years) for co-infected indi-
viduals, 41 years (IQR, 32 - 47) for HIV patients and 32
(IQR, 29 - 38) for HC, respectively. There was a predomi-
nance of the female gender among HIV and co-infected
individuals (86,3% and 86.4% respectively) and predom-
inance of the male gender among HC (80%; see table 1).
Almost half of co-infected and HIV patients were classified
as stage 2 for HIV clinical disease (58.4% and 56.0% for
co-infected and HIV patients respectively) based on the
WHO criteria [33]. None of the co-infected or HIV
patients was at stage 4 of HIV clinical disease (table 1).
HAM/TSP or ATL cases were not detected in subjects of
any groups.
Co-infected and mono-infected were comparable regard-
ing clinical presentation of opportunistic diseases (table
2).
Blood samples
Ten milliliters of venous whole blood were requested
from each volunteer. The blood was collected aseptically
into a 5 ml vacuum tube with K3EDTA and a 5 ml vacuum
tube for serum separation (Becton-Dickinson Vacutainer
Systems, USA). Blood specimens were delivered at the lab-
oratory within four hours of collection.
HIV Serology
All patients enrolled in this study were screened for anti-
HIV 1/2 antibodies at the Voluntary Counseling and Test-
ing (VCT) services of the Mozambican Health Center.
Patients were tested for HIV according to the Mozambican
National protocol consisting of a sequential algorithm of
two immunochromatographic rapid tests. All individuals
were first screened using the Determine HIV-1/2 test
(Abbott Laboratories, Japan). All specimens reactive on
the screening assay were further tested using the Uni-Gold
HIV test (Trinity Biotech, Ireland). Individuals reactive on
both assays were considered positive for HIV-1/2 infec-
tion.
HTLV Serology
All samples were screened for anti-HTLV-1+2 antibodies
using the qualitative EIA Murex HTLV-1 + 2 (Murex Bio-
tech Limited, UK). Specimens reactive on the EIA were
confirmed by a Western blot assay (HTLV BLOT 2.4,
Genelabs®  Diagnostics, Switzerland). All patients with
reactivity to antigens encoded by the GAG gene (p19 with
or without p24) and to two antigens encoded by the ENV
gene (GD21 and rgp46-I) were considered to be infected
by HTLV-1 according to the instructions provided by the
manufacturer. All HTLV positive samples in our study
population were typed as HTLV-1 by Western blot.
T cell immunophenotyping
Phenotypic analysis of circulating T lymphocytes was per-
formed through four colour flow cytometry on fresh
EDTA-anticoagulated whole blood using a FACSCalibur™
flow cytometer (Becton-Dickinson Biosciences, USA). T
cells counts were obtained based on a lyse-no wash proto-
col using CellQuest Software for acquisition (BD Bio-
sciences). Cells were stained with the following
fluorescent-labeled anti-human monoclonal antibodies
CD4-APC, CD8-PerCP, CD25-PE, CD62L-FITC, CD45RA-
FITC. CD45RO-PE, CD38-PE (all from BD Biosciences).









Median 40.0 41.0 32.0
IQR 34.0 - 48.0 32.0 - 47.0 29.0 - 38.0 0.123*
Gender
Male 4 (13.8%) 8 (13.6%) 12 (80%)
Female 25 (86.3%) 51 (86.4%) 3 (20%) 0.000**
HIV clinical stage***
I 7 (24.1%) 14 (23.7%)
II 17 (58.4%) 33 (56.0%)
III 5 (17.2%) 12 (20.3%) 0.587**
* One Way Anova; ** Chi square; ***as defined by WHO[30];
HIV/HTLV-1, HIV/HTLV-1 co-infected; HIV, HIV mono-infected; HC, healthy controlsBMC Infectious Diseases 2009, 9:211 http://www.biomedcentral.com/1471-2334/9/211
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Analyses were performed using the Summit software v
4.3.2, 2006 (Dako Cytomation, Inc., Fort Collins, USA).
HIV-1 subtyping
Samples from co-infected and mono-infected individuals
were sequenced for HIV-1 subtyping. A 297-bp fragment
encompassing full sequence of the protease gene was
amplified using nested PCR. The outer primers PRT15F 5'
TGAAAGATTGTACTGAGAGACAGG 3'/K2R 5' GTCAAT-
GACATACAGAAGTTAGTGGGAAAA 3' were used in first-
round PCR, and DP10F 5' CAACTCCCTATCAGAAGCAG-
GAGAAG 3'/RVP3R 5'-CCATACAATACTCCAGTATTT-
GCC-3' were used as inner primers during the second-
round of nested PCR. The conditions for both rounds of
PCR were described previously [36]. Amplified DNA was
quantified, purified and sequenced under PCR conditions
described elsewhere [37], using the primers from the sec-
ond-round PCR. The genetic subtypes were determined
using the amino acid sequences of the protease genes,
deduced from the nucleic acid sequences, and were com-
pared to a subtype B consensus sequence from the Stan-
ford HIV Protease Sequence database http://
hivdb.stanford.edu/hiv/.
The analysis of the Mozambique sequence with HIV Drug
Resistance database showed that all samples sequenced
(20 mono-infected and 24 co-infected) were subtype C in
protease gene with profile of similarity of 98% compared
with sequence subtype C from the Stanford HIV Protease
Sequence database.
Stool samples
Stools were collected into a sterile, wide mouth, leak-
proof container with a tight fitting lid containing a pre-
servative solution. Stools were kept at room temperature
until delivery at the study setting within six hours of col-
lection. Small amounts of stool specimens were placed on
microscope slides and mixed with 0.9% NaCl solution to
prepare wet mount smears. Slides were then examined
under a light microscope to screen for cysts of Giardia lam-
blia, Entamoeba hystolitica, Entamoeba coli and Balantidium
coli, ova of Ascaris lumbricoides, Trichuris trichiura and Ancy-
lostoma duodenale and larvae of Strongyloides stercolaris.
Statistical analysis
Data was analyzed using the statistics package STATA 9.0
(College Station, Texas: StataCorp, USA, 2005).
Taking into consideration that the major goal of our study
was to compare activation markers between co-infected
versus HIV mono-infected patients, two sample compari-
son means with a ratio 1:2 (case:control) was used to
determine the required sample size in these groups. Due
to lack of information regarding comparison of activation
markers between these groups, we calculated a sample
size enough to detect a least a difference of 10% in the
mean of these cells frequencies with a standard deviation
of 14 at a significance level of 5%.
The Mann-Whitney test and the One Way Anova trend test
were used to compare the differences among numerical
variables in the three groups. Associations between cate-
gorical variables were determined using the Pearson Chi-
square test, the Fisher exact test or the Chi-square trend
test, as appropriated.
Results
HIV/HTLV-1 co-infected individuals present higher and 
stable CD4+ T cell counts
We first showed that HIV/HTLV-1 co-infected individuals
exhibited a higher absolute and relative CD4+ T cell counts
(median: 525 cells/mm3, versus 274 cells/mm3, p = 0.000
and 24.9% versus 15.9%, p = 0.000, see table 3) and a
higher CD4+/CD8+  T cell ratio (0.5 versus 0.30, p =
0.004), when compared with the HIV mono-infected
group. Moreover, CD4+ T lymphocytosis in co-infected
Table 2: Clinical presentation of study groups





Assymptomatic 7 (24.1) 14 (23.7)
Papular pruritic eruptions 3 (10.3) 14 (23.7)
Dermatitis 2 (6.9) 2 (3.4)
Seborrhoeic dermatitis 2 (6.9) 0 (0.0)
Folliculitis 0 (0.0) 1 (1.7)
Herpes zoster < 5 years 3 (10.3) 4 (6.8) 0.570
TInea capitis 5 (17.2) 8 (13.6)
Candidiasis 3 (10.3) 4 (6.8)
Tuberculosis < 1 year 1 (3.5) 4 (6.8)
Weight loss > 10% 3 (10.3) 7 (11.9)
Chronic diarrhoea 0 (0.0) 1 (1.7)
* Fisher chi square testBMC Infectious Diseases 2009, 9:211 http://www.biomedcentral.com/1471-2334/9/211
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individuals was stable irrespective of their HIV clinical
stage, thus contrasting with the gradual loss of CD4+ T
cells from HIV clinical stage I through stage IV seen in the
mono-infected group (figure 1). Both groups were similar
regarding CD8+ T cell absolute counts but co-infected
individuals presented lower CD8+ T cell relative counts (p
= 0.505 and p = 0.009, respectively; see table 3). These pat-
terns were the same in both males and females (data not
shown).
Higher proportions of CD4+ T cells bearing an activated 
phenotype in HIV/HTLV-1 co-infected individuals
The data described above, on the differences in CD4+ T
cell counts between co-infected versus  HIV patients,
pointed to a differential activation state of T cells in these
patients. In fact, when compared to HIV or to HC partici-
pants, co-infected individuals presented significantly
higher membrane levels of CD25 and CD45RO on CD4+
T cells (0.007 and 0.040 respectively, figure 2C and 2G).
Also the density of CD38 molecules on the surface of
CD8+ T cells was higher in co-infected when compared to
HIV and HC participants, although not statistically signif-
icant, (figure 3 and table 3). The relative numbers of
CD8+CD38+  and CD8+CD45RO+  cells in co-infected
although statistical significantly higher than HC (p =
Table 3: Distribution of T cell subsets in peripheral blood from HIV/HTLV-1 co-infected, HIV mono-infected and healthy Mozambican 
subjects






CD4+ T cell counts (cells/mm3)
Median 525a 274 472
IQR 310 - 827 183 - 436 412 - 775
CD4+ T cell counts (%)
Median 24.9 a, b 15.9 45.0
IQR 19.0 - 32.7 9.4 - 21.0 37.0 - 48.0
CD8+ T cell counts, cells/mm3
Median 1002b 937 302
IQR 649 - 1090 606 - 1358 190 - 391
CD8+ T cell counts, %
Median 46.8a, b 54.2 23.0
IQR 36.2 - 53.0 42.7 - 61.3 21.0 - 29.0
CD4+ T/CD8+ T ratio
Median 0.5a, b 0.3 1.8
IQR 0.3 - 0.8 0.2 - 0.4 1.2 - 2.5
CD8+ CD38+ T cells (MFI)
Median 341.5 279.9 209.7
IQR 285.1 - 367.1 225.4 - 373.3 209.7 - 225.4
HIV-1 RNA viral load (copies/mL)
Median 56,385 37,573
IQR 14,749 - 277,570 11,322-176,837
One ANOVA corrected by Bonferoni was used to compare groups.
HIV/HTLV-1, HIV/HTLV-1 co-infected; HIV, HIV mono-infected; HC, healthy controls; MFI, Median Fluorescence Intensity
a p < 0.05 comparison co-infected versus HIV mono-infected
b p < 0.05 comparison co-infected versus healthy controls
Absolute CD4+ T cell counts in different HIV clinical stages,  among different HTLV status Figure 1
Absolute CD4+ T cell counts in different HIV clinical 
stages, among different HTLV status. There is a con-
sistent and stable high absolute CD4 T cell count in co-
infected individuals, contrasting with the progressive 
decrease of this cell subset in the monoinfected group, 
related to the progression of HIV disease. p value for Anova 
trend test was 0.000 and 0.945 for HIV/HTLV-1 and HIV 
groups respectively.BMC Infectious Diseases 2009, 9:211 http://www.biomedcentral.com/1471-2334/9/211
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Distribution of T cell subsets in HIV/HTLV-1 co-infected, HIV mono-infected and healthy Mozambican subjects Figure 2
Distribution of T cell subsets in HIV/HTLV-1 co-infected, HIV mono-infected and healthy Mozambican sub-
jects. Co-infected patients presented higher CD4+CD45RO+ (memory cells, C), CD8+CD38+ (activated cells, E) and lower 
CD4+CD45RA+ (naïve cells, A) and CD4+CD62L+ (naïve cells, H). *p < 0.05, as ascertained by One Way Anova. HIV/HTLV 
= coinfected, HIV = mono-infected by HIV and HC = healthy controls.BMC Infectious Diseases 2009, 9:211 http://www.biomedcentral.com/1471-2334/9/211
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0.000 for both CD8+CD38+ and CD8+CD45RO+ respec-
tively, figures 2D and 2F) was only slightly higher than
HIV individuals (median: 51.3%, versus 41.2%, p = 0.652
for CD8+CD38+ and 37.4% versus 31.0%, p = 0.512 for
CD8+CD45RO+ respectively, figures 2D and 2F).
All three groups were similar regarding the expression of
CD38 on CD4+ T cells (figure 2E).
Naïve cells were phenotyped for the expression of
CD45RA and CD62L on CD4+ and CD8+ T cells respec-
tively. Co-infected and HIV individuals exhibited lower
levels of CD45RA (p = 0.023 and 0.037 respectively) and
CD62L (p = 0.026 and 0.041 respectively) on CD4+ T lym-
phocytes, when compared to HC, Such a loss of naïve cells
was more pronounced in the co-infected group (figures
2A, H and 3).
Of interest, stool evaluation revealed no significant differ-
ences in helminthic or protozoan loads among the three
groups of patients (data not shown), indicating that the
relative role of parasites in inducing lymphocyte activa-
tion is likely similar in the various groups.
Activation markers on T cells correlate with HIV clinical 
stage
The small sample size of our study was a limitation to
assess the changes in the activation by HIV clinical stage.
Therefore, although a statistical analysis was not possible
to perform, we stratified the analysis of these subsets by
HIV clinical stage in an intent to define a pattern (figure
4). Our data found that the relative numbers of
CD8+CD45RO+ (figure 4D) T cells remained unchanged
from HIV clinical stages I to III. By contrast, there was an
increase in the expression of CD38 in both CD4+ and
CD8+ T cell subsets (figures. 4E-F) and a decrease of
CD4+CD62L+ and CD8+CD45RA+ (figure 4B) subsets
from clinical stage I through III in both groups. The fre-
quency of CD4+CD45RO+ (figure 4A) CD4+CD25+ (fig-
ure 4G) subsets was higher from stage I through III among
Activated and naïve T cell profiles HIV/HTLV-1 co-infected, HIV mono-infected and healthy Mozambican subjects Figure 3
Activated and naïve T cell profiles HIV/HTLV-1 co-infected, HIV mono-infected and healthy Mozambican sub-
jects. Dot plots show the typical phenotype of activated (upper panels) and naïve T lymphocytes (lower panel). Upper panels 
reveal that co-infected patients presented with higher density of CD38 molecules on T CD8+ T cells. Co-infected patients pre-
sented lower frequency of CD4+CD62L+ cells when compared with HIV positive patients and health controls (lower panel).BMC Infectious Diseases 2009, 9:211 http://www.biomedcentral.com/1471-2334/9/211
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Changes in the subsets of T cells in the distinct HIV clinical stages Figure 4
Changes in the subsets of T cells in the distinct HIV clinical stages. CD8+CD45RO+ (D) remained unchanged in the 
various HIV clinical stages in both groups. CD38+ on CD4+ and CD8+ T cells (E and F), CD4+CD25+ and CD4+CD45RO+ 
subsets were increased from clinical stage I through III in both groups. CD4+CD45RA+ (A), CD8+CD45RA+ (B) and 
CD4+CD62L+ (H) decreased from stage I through III. Co-infected patients in the clinical stage III for CD4+CD25+ and 
CD4+CD45RO+ and CD4+CD45RA+ did not follow the pattern observed in HIV mono-infected individuals. I = HIV Clinical 
Stage I, II = HIV Clinical Stage I,  III = HIV Clinical Stage III.BMC Infectious Diseases 2009, 9:211 http://www.biomedcentral.com/1471-2334/9/211
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HIV mono infected patients. Rather unexpectedly, among
co-infected patients the frequencies of these subsets were
lower in the clinical stage III when compared to clinical
stage II. Similarly in respect to the frequency of the
CD4+CD45RA+ subset (figure 4A) there was an decrease
from stage I through stage III among HIV monoinfected
patients. Surprisingly, among co-infected patients, the fre-
quency of cells in the clinical stage III was higher than in
the clinical stage II. It is possible that the small sample size
in each clinical stage may explain these unexpected find-
ings
HIV-1 viral load positively correlates with the 
enhancement of T cell activation markers in both co-
infected and HIV groups
Although weak, there was an inverse correlation between
the proportions of CD4+CD45RA+ naïve cells and HIV-1
viral load. Co-infected group appeared to present a better
correlation when compared to HIV group (r = -0.224 ver-
sus -0.204 respectively, figures 5A-B), but the difference
was not statistically significant.
In contrast, there was a positive correlation between the
proportions of CD8+CD38+ cells and HIV-1 viral load.
Again co-infected group presented a slightly higher corre-
lation, but such a difference was not statistically signifi-
cant (r = 0.536 versus 0.482 respectively, figures 5C-D).
Discussion
HIV and HTLV-1 have emerged as common co-pathogens
especially in areas or groups where both viruses are circu-
lating [5,9,38,39]. Nevertheless, the impact of HTLV-1 on
HIV disease progression is still a matter of debate with
controversial results [10-14,30,40]. Here, for the first time
we conducted a case control study in an African setting,
aiming to determine the impact of HTLV-1 infection on
HIV disease. In fact, to our knowledge, the present study
is pioneer in the region, since it was conducted in HAART
naïve patients, on a well controlled cross-sectional basis.
Previous studies were conducted mainly in South and
North Americas where the epidemiology of HIV infection
and other diseases is quite different from that seen in sub-
Saharan African countries [29,30].
We found no evidence of HTLV-2 in our study population.
This is in keeping with two recent studies conducted
among blood donors in Maputo city[34,35] and suggest
that only HTLV-1 (but not HTLV-2) circulates in Mozam-
bique.
As expected, co-infected individuals presented a stable
CD4+ T lymphocytosis irrespective of their progression to
AIDS, contrasting with the depletion of CD4+  T cells
counts observed among HIV patients over time. To date, it
is well established that cell immortalization and transfor-
mation induced by Tax and Rex proteins encoded by
HTLV-1 genes constitute major events related to uncon-
trolled CD4+ T cell growth and proliferation [41,42].
The intriguing progression to AIDS in the presence of nor-
mal or high levels of CD4+T cells counts suggest these to
be functionally altered. Consensus exists that both HIV
[43,44] and HTLV [24,25,45] separately induce functional
modifications on T cells populations, characterized
among others by a decrease of naïve populations and
higher levels of cell activation when compared with unin-
fected individuals.
Here we found that co-infected individuals presented
markedly lower expression of CD45RA+ (a phenotypic
marker of naïve T lymphocytes) on CD4+ T cells. Naïve
cells are considered the first cells to be depleted in the
presence of immune activation [46,47] and represent one
of the hallmarks of HIV infection [48]. The magnitude
and impact exerted by naïve T cells erosion on HIV disease
progression remain to be defined. Although not fully
understood, there is a consensus that for both HIV and
HTLV-1, the loss of naïve cells has been linked, among
others, to, (i) a homeostatic mechanism to replenish the
cells being killed (ii) a massive recruitment of naïve cells,
partially imposed by the mechanisms driving the activa-
tion and (iii) the impairment of T cell production
[19,20,46-49].
In our study, the erosion of the naïve compartment was
further confirmed by evaluating the expression of CD62L,
another marker for naïve T lymphocytes, usually lost
upon activation. As expected, there was a dramatic loss of
CD4+CD62L+ lymphocytes in the co-infected group, when
compared to HIV mono-infected and HC groups. Impor-
tantly, these differences were further confirmed when we
compared the groups in terms of naive cell absolute
counts (data not shown) arguing against an indirect effect
of higher percent counts of memory cells. Whether there
is an impairment of T cell production, if they are dying
faster or if more cells being recruited from the naïve T cell
pool into activated/memory cell compartment remain to
be determined.
Not surprisingly, this loss of naïve cells in co-infected
individuals was accompanied by higher frequencies of
memory and activated cells as measured by CD45RO+
(memory), CD38+ and CD25+ (activated) cell markers. In
fact, co-infected individuals presented with higher pro-
portions of CD45RO+ on CD4+ T cells when compared to
the HIV and HC groups. These findings are in agreement
with previously data [45,46,50,51], Similarly, the relative
number of CD4+CD25+ cells seen in co-infected patients
was higher than what was found in HIV and HC individ-BMC Infectious Diseases 2009, 9:211 http://www.biomedcentral.com/1471-2334/9/211
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uals. It is conceivable that the increase of CD4+CD25+
cells is a consequence of the virus-driven induction of IL-
2/IL-2 receptor expression by tax, as previously reported
[12,23,52]. Interestingly, the frequency of CD38+cells
within the CD8+ T cell compartment but not in CD4+ T
cells was increased in co-infected and HIV when com-
pared to HC. This is in keeping with the results showed in
a case-control study conducted among HAM/TSP patients
[24]. Although we did not find differences in the fre-
quency of CD38+ cells, either in CD8+ or CD4+ T cells, we
found that co-infected patients presented higher expres-
sion of CD38 in CD8+ T cells (as ascertained by Median
Fluorescence Intensity measurements) when compared to
HIV patients. Nevertheless differences were not statically
significant.
Noteworthy, increased expression of CD38 on the surface
of CD8+ T cells have long been considered an even better
prognostic predictor of progression to AIDS and response
to HAART than HIV viral load itself [53,54]. This is rele-
vant due to the fact that such parameter is being proposed
to be included in clinical settings to monitor HIV disease
progression [55].
Correlation between naïve CD4 (CD4+CD45RA+) or activated CD8 (CD8+CD38+) T lymphocytes with HIV-1 viral Load Figure 5
Correlation between naïve CD4 (CD4+CD45RA+) or activated CD8 (CD8+CD38+) T lymphocytes with HIV-1 
viral Load. Panels A and B depict a negative correlation between CD4+CD45RA+ (naive cells) and HIV-1 viral load in both 
co-infected and HIV-1 subjects. By contrast, lower panels show a positive correlation between CD8+ CD38 (activated cells, C 
and D) and HIV-1 viral load in both co-infected and HIV-1 subjects.BMC Infectious Diseases 2009, 9:211 http://www.biomedcentral.com/1471-2334/9/211
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It is now widely accepted that the presence of chronic acti-
vation is a major factor influencing the pathogenesis of
HIV in Africa [56]. HTLV-1 is a strong activator of immune
system. Immune activation and exaggerated immune
response has been demonstrated to be the main pathoge-
netic mechanism involved in the HTLV-1 associated
inflammatory syndromes[24,57-59]. The immunodomi-
nant Tax protein encoded by HTLV transactivates and
modulates a large number of genes playing a key role in
triggering several pathways leading to cell activation[60-
62]. Available data demonstrate that a large proportion of
asymptomatic carries progress with high levels of immune
activation[63].
On the basis of the patients' age and their HAART naïve
status, we believe that HTLV-1 infection preceded HIV
infection. Considering that individuals chronically
infected by HTLV progress with immune activation, it is
conceivable that these patients acquire HIV infection in a
pre-activated immune milieu, and the presence of
immune hyper activation not only turns them more sus-
ceptible to acquire HIV, but also to progress faster to a
poor prognosis.
Cases and controls were matched by age and clinical stage
(WHO) so that to be comparable in terms of clinical pres-
entation (see table 2), Clinical staging system is per-
formed on the basis of patient's clinical presentation. This
information is important when interpreting the differ-
ences in the activation markers between these groups.
Another aspect deserving discussion is the helminthic
infection as a factor involved in immune activation, par-
ticularly in Southern Africa [3,64]. Accordingly, a differen-
tial presence of parasitic infection in our patients could
bias our results. However, this does not seem to be the
case since in all groups evaluated, the degree of protozoan
and helminthic infections were similar. Of note, all sam-
ples sequenced in both groups were founded to be HIV
subtype C, ruling out any linkage between HIV subtype in
mono and co-infected groups, and immunological/clini-
cal behavior.
Conclusion
In conclusion, although HIV/HTLV-1 co-infected individ-
uals quantitatively maintain a normal or high CD4+ T cells
counts, these cells are likely functionally altered present-
ing with a dramatic decrease of naïve cells and higher acti-
vation patterns. Yet, if these changes account for a faster
progression to AIDS remains to be determined.
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